Answers are grounded in this paper and cite their sources.
6-MeG adducts and MMR-deficiency leads to tolerance of lesions, resistance to TMZ and further DNA mutations. In this article, two strategies to overcome TMZ resistance are discussed: (1) synthesis of imidazotetrazine analogues - designed to retain activity in the presence of MGMT or loss of MMR; (2) preparation of imidazotetrazine-nanoparticles to deliver TMZ preferably to the brain and tumour site. Our promising results encourage belief in a future where better prognoses exist for patients diagnosed with this devastating disease.
No takes yet. Share an insight, caveat, or question.
Bouzinab et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: